Xtant Medical Holdings Partners with B2i Digital to Showcase Orthobiologics Platform to Investors

Xtant Medical Holdings has announced a strategic partnership with B2i Digital aimed at enhancing investor understanding of its orthobiologics platform and long-term value proposition. This initiative is designed to deliver centralized, investor-focused content, catering to both retail and institutional audiences. Xtant Medical, recognized as a global leader in regenerative medicine products for orthopedic and neurosurgical specialists, operates a vertically integrated model that encompasses a wide range of products from bone-healing grafts to amnion products, backed by a robust research and development pipeline.

David Shapiro, CEO of B2i Digital, pointed out the importance of showcasing Xtant Medical at a pivotal moment in its expansion. The company's broad coverage of key orthobiologic categories, combined with its impressive revenue growth trajectory, presents a noteworthy investment opportunity in the medical technology sector. Sean Browne, CEO of Xtant Medical, underscored the partnership's objective to effectively communicate the company's growth narrative and the intrinsic value of its biologics platform to the investment community.

The company reported fiscal year 2024 revenue of $117.5 million, a 29% increase from the previous year, underscoring its strong business fundamentals. With access to a vast market through 450 integrated delivery network contracts and a network of more than 670 independent distributors, Xtant Medical is well-positioned in the $2.5 billion U.S. orthobiologics market, which is a segment of the larger $10.1 billion global spine market. For more information on Xtant Medical's innovative solutions, visit https://www.xtantmedical.com.